NanoVibronix Inc. (NAOV) - מקדם חוב לטווח ארוך להון

High patent barriers for WoundWand and strict FDA oversight protect the business of NanoVibronix, Inc. (NAOV), which relies on growing demand in urology and the outpatient sector. Stock price volatility reflects a dependence on debt obligations, where the indicator stands at 0.00. Management, experts in acoustic waves, is currently developing portable tissue healing systems to expand insurance reimbursements and sales.

This metric measures the share of long-term liabilities within the equity structure, determining the issuer's financial stability. The ratio of loans with a maturity of more than one year to equity reveals the degree of debt load. The current value of 0.00 allows for an assessment of leverage risks. By analyzing the ratio of long-term loans to equity, an investor can identify the resource base for scaling. This is critical for NanoVibronix, Inc. (NAOV) during the expansion of the UroShield line within the hospital segment.